Mon, January 27, 2025

by: Gizmodo

Chinese AI DeepSeek Deep Sixes OpenAI on the App Store, Stocks Tank

Chinese AI chatbot DeepSeek has displaced OpenAI's ChatGPT as the most downloaded app on the Apple App store and the market is panicking. Stocks for major AI connected companies like NVIDIA fell on Monday morning following the news.

by: FXStreet

Tech turmoil: DeepSeek disruption sends markets into a tailspin

Use a large oven proof skillet and heat equal parts of butter and olive oil over med hi heat. Add the seasoned fillets skin-side-down and pan-sear for 3 minutes. Flip and place the pan in the oven for 4 mins more.

by: MSN

What to expect from stock markets ahead of Budget 2025? Kranthi Bathini's take

India's stock market faces a tug-of-war between bulls and bears, with foreign outflows countered by domestic buying. Key triggers include Q3 earnings, global cues, and the upcoming Union Budget. Stock-specific strategies are crucial in navigating volatility.

by: Indiatimes

Capital Numbers shares list with 4% premium on BSE SME platform

by: MSN

If You'd Invested $100 in PayPal Stock 10 Years Ago, Here's What It Would Be Worth Today

PayPal is the most popular digital payments company, with over 400 million users and over 6 billion payments processed per quarter. But while the online payment behemoth is the clear leader in

by: MSN

Goldman Sachs raises AbbVie stock price target to $208

Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the pharmaceutical company's shares to $208.00, up from the previous target of $205.00.

by: MSN

Is Boston Scientific (BSX) Among the Best Fundamental Stocks to Buy Now?

We recently compiled a list of the 12 Best Fundamental Stocks to Buy Now. In this article, we are going to take a look at where Boston Scientific Corporation (NYSE:BSX) stands against other best fundamental stocks to buy now.

by: Investing

DeepSeek's 'Sputnik moment' prompts investors to sell big AI players

SINGAPORE (Reuters) - Nasdaq futures slumped and technology shares slid in Japan on Monday as surging popularity of a Chinese discount artificial intelligence model wobbled investors' faith in the profitability of AI and the sector's voracious demand for high-tech chips.

by: MSN

JMP Securities maintains GENI stock with $11 target

JMP Securities reiterated their Market Outperform rating and $11.00 price target for Genius Sports Ltd. (NYSE: GENI), following a recent equity raise by the company on January 15, 2025. The firm's analyst noted that Genius Sports opted for the fundraising at a time when its shares were trading close to the 30-day moving average and 14% below the 52-week high,

by: MSN

JMP Securities maintains $14 target on Inspired Entertainment stock

Inspired Entertainment Inc (NASDAQ:INSE), currently trading at $9.45, received a vote of confidence from JMP Securities, with analyst Jordan Bender reiterating a Market Outperform rating and a $14.00 price target.

by: MSN

AI proxy stocks Siemens Energy, Munster tumble on DeepSeek concerns

Shares of Siemens Energy AG (ETR:ENR1n) (XETRA:ENR) plummeted 17.2% as European markets faced a broad sell-off, particularly in the technology sector, following the introduction of a new low-cost artificial intelligence (AI) model by startup DeepSeek.

by: MSN

JMP INITIATES COVERAGE ON DIGITAL INFRASTRUCTURE STOCKS

JMP Securities initiated coverage on a group of companies in the digital infrastructure sector, assigning Market Outperform ratings to seven key players. The firms receiving this positive outlook include Digital Bridge (NYSE:DBRG),

by: AOL

1 Unstoppable ETF That Could Turn $350 per Month Into $1 Million

Investing in the stock market today can be a bit concerning, given the S&P 500's elevated levels and many stocks trading at high valuations. Putting money every month into a diverse exchange-traded fund (ETF) can be an excellent way to ensure you aren't worried about timing the market while also putting yourself in a great position to grow your portfolio's balance over the long term.

by: MSN

Prediction: These 2 "Magnificent Seven" Stocks Will Be AI's Biggest Winners by 2030 (Hint: Neither One Is Nvidia)

Artificial intelligence (AI) has garnered so much attention over the past couple of years. Experts believe this is a game-changing technology that will impact virtually all industries one day. Investors,

by: MSN

Does This New Bullish Tailwind for Dogecoin Make It a Buy?

Dogecoin (CRYPTO: DOGE) just got exposure to what might become a strong new tailwind. While it will take at least a few months for it to develop, it could provide the king of the meme coins with some additional liquidity,

by: MSN

3 of the best Australian stocks to buy now

Let's see why Bell Potter has named these stocks as best buys. The post 3 of the best Australian stocks to buy now appeared first on The Motley Fool Australia.

by: MSN

Motilal Oswal Innovation Opportunities Fund and 7 other mutual fund NFOs to open for subscription this week

Kotak BSE Sensex Index Fund, an open-ended scheme tracking the BSE Sensex, opens for subscription on January 27 and closes on February 10, with continuous sale and repurchase starting February 17. The fund aims to deliver returns mirroring the total returns of the BSE Sensex,

by: AOL

2 Vanguard ETFs to Buy With $500 and Hold Forever

When you think of investing in stocks, you probably think of considering each company one by one, researching that particular player -- and then buying if the investment case looks solid. You can do this by getting in on a good exchange-traded fund (ETF),

by: MSN

2 High-Yield Dividend Stocks to Buy With $300 and Hold Forever

Investing in dividend stocks can be a great way to set up a durable income stream. The best ones can provide you with stable and growing recurring dividend income that can last a lifetime. Realty Income (NYSE: O) and Mid-America Apartment Communities (NYSE: MAA) have been very durable dividend stocks over the decades.

by: MarketWatch

Stock Market Today: Dow, S&P 500 set to fall, Nasdaq to dive on DeepSeek worries; Nvidia, ASML, Microsoft shares rocked

In international markets, chipmaking and electrification companies saw pressure on the fears over the DeepSeek AI service. SoftBank -- the company that said it would fund up to $500 billion in AI infrastructure as well as the main shareholder of microchip designer ARM -- saw its stock dive 8%.

by: MSN

Lure of diversification, higher returns and global exposure driving Indian investors to US markets: Subho Moulik

Subho Moulik, CEO of Appreciate, explains the increased interest of Indian investors in US markets, emphasizing diversification, higher returns, and advanced sector opportunities like AI and biotech.

by: Forbes

5 Promising High-Growth Sectors To Invest In 2025

Finding, analyzing and choosing sectors to invest in can be difficult. Consider these potential high-growth areas in the year ahead.

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Veru Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of TomTom N.V. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of TriSalus Life Sciences, Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Duos Technologies Group, Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Evaxion Biotech A/S in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Alaunos Therapeutics, Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Webstar Technology Group, Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of NextPlat Corp in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Suzuki Motor Corporation in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Jasper Therapeutics, Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of WISeKey International Holding AG in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Data Storage Corporation in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of BioXcel Therapeutics, Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of AM TELNET CORP in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Surge Battery Metals Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Mast Therapeutics Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of comScore, Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Selectis Health, Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of VELTI in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of United Lithium Corp. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Dimon Inc in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Unity Biotechnology, Inc. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Turbo Energy, S.A. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Polestar Automotive Holding UK PLC in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of North Peak Resources Ltd. in recent trading

by: WOPRAI

As of Jan 27th, 2025, there has been substantial selling of Cidara Therapeutics, Inc. in recent trading

Goldman Sachs raises AbbVie stock price target to $208

Goldman Sachs updated its financial model for AbbVie (NYSE:ABBV), leading to an increase in the price target for the pharmaceutical company's shares to $208.00, up from the previous target of $205.00.

Goldman Sachs has increased its price target for AbbVie Inc. to $208 from $173, maintaining a "buy" rating on the stock. This adjustment reflects optimism about AbbVie's future performance, particularly due to the potential of its new drug, Skyrizi, which is expected to drive significant revenue growth. The stock has already seen a 10% increase year-to-date, and with the new price target, Goldman Sachs analysts suggest that AbbVie could see further gains, supported by its robust pipeline and strategic market positioning.

Read the Full MSN Article at:
https://www.msn.com/en-us/money/top-stocks/goldman-sachs-raises-abbvie-stock-price-target-to-208/ar-AA1xWese